Researchers have discovered an investigational new drug PSD502, which is highly effective in treating primary premature ejaculation (PE).

Shionogi Pharma, Inc., a U. S. based group company of Shionogi & Co., Ltd., has released facts summing up the outcomes of two key researches of PSD502, a topical metered dose spray being developed for treating premature ejaculation.

The researchers assessed a combined total of 556 (randomized) and 536 (treated) males with primary PE in the United States, Canada and Europe over a three-month period, with over 23,000 exposures to PSD502 recorded, the data showed that males who were treated with PSD502 five minutes before intercourse by applying PSD502 through a topical metered dose spray experienced a time to ejaculation 5.5 times longer as compared to those who used a placebo spray with the actual average measurement in minutes for drug and placebo.

A co-primary endpoint also viewed ejaculatory control as well as satisfaction.

Point differences of 6.1 and 5.3 were discovered between the PSD502 group and placebo in ejaculatory control and satisfaction domains, respectively.

Ira D. Sharlip, clinical trial investigator and clinical professor of urology at the University of California, San Francisco, stated, "Combined results from the PSD502 pivotal studies are very exciting and this is a significant milestone."

These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco. (With Inputs from Agencies)